Product Description
Mechanisms of Action: PNP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BCX4208-203 | P2 |
Completed |
Unknown |
2012-07-01 |
|
| BCX4208-204 | P2 |
Completed |
Kidney Diseases |
2012-07-01 |